论文部分内容阅读
目的肺结核合并血清乙型肝炎病毒标致物（ＨＢＶＭ）大三阳（表面抗原、ｅ抗原、核心抗体）的患者在抗痨化疗过程中，辅以保肝治疗的效果观察。方法我院１９８８～１９９８年收治的初治肺结核合并乙肝大三阳者，随机分为甲乙两组，甲组为抗痨化疗＋保肝治疗，乙组为单纯抗痨化疗组，观察保肝治疗的疗效。结果乙肝大三阳的结核病患者在抗痨化疗同时，辅以保肝治疗，延缓肝损害和黄疸的发生时间，两组发生时间进行Ｔ检验，Ｔ＝６．８２，Ｐ＜０．０１。明显降低肝损害和黄疸的发生率，单纯抗痨组肝损害和黄疸的发生率为５５．５％，抗痨加保肝组肝损害和黄疸的发生率为１３％，Ｘ２＝１２．４８０，Ｐ＜０．００５。
The purpose of tuberculosis combined with serum hepatitis B virus (HRV) three positive (surface antigen, e antigen, core antibody) in patients with anti-tuberculosis chemotherapy, combined with the effect of liver protection observed. Methods In our hospital from 1988 to 1998 admitted to the newly diagnosed tuberculosis combined with hepatitis B three positive, were randomly divided into two groups, A group of anti-tuberculosis chemotherapy plus hepatoprotective therapy, B group was anti-tuberculosis chemotherapy group, observation of hepatoprotective therapy Efficacy. Results HBeAg and tuberculosis patients were treated with anti-tuberculosis chemotherapy combined with hepatoprotective therapy to delay the onset of liver damage and jaundice. T-test was performed at the time of occurrence of both groups (T = 6.82, P <0.01). Significantly reduced the incidence of liver damage and jaundice, the incidence of liver damage and jaundice was 55.5% in pure anti-tuberculosis group, the incidence of liver damage and jaundice was 13% in anti-tuberculosis plus liver protection group, X2 = 12.480, P <0.005.